Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates through two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment produces and sells research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, and research animal diagnostic services; endotoxin and microbial detection products and services; and avian vaccine products and services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program manage
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-6.09%||Sales Growth - Q/Q||-2.77%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||6.9%||ROE||18.39%||ROI||8.26%|
|Current Ratio||2.27||Quick Ratio||1.95||Long Term Debt/Equity||2.2||Debt Ratio||0.39|
|Gross Margin||36.67%||Operating Margin||13.72%||Net Profit Margin||9.67%||Dividend Payout Ratio|
|Cash From Financing Activities||-63.73 M||Cash From Investing Activities||-36.49 M||Cash From Operating Activities||96.68 M||Gross Profit||132.78 M|
|Net Profit||48.51 M||Operating Profit||55.73 M||Total Assets||1.89 B||Total Current Assets||629.65 M|
|Total Current Liabilities||276.53 M||Total Debt||772.77 M||Total Liabilities||1.18 B||Total Revenue||339.57 M|
|High 52 week||148.55||Low 52 week||104.82||Last close||139.53||Last change||0.92%|
|RSI||69.48||Average true range||3.4||Beta||0.74||Volume||208.32 K|
|Simple moving average 20 days||4.9%||Simple moving average 50 days||5.02%||Simple moving average 200 days||3.11%|
|Performance Week||1.76%||Performance Month||10.41%||Performance Quart||8.16%||Performance Half||8.63%|
|Performance Year||11.62%||Performance Year-to-date||23.28%||Volatility daily||1.29%||Volatility weekly||2.87%|
|Volatility monthly||5.89%||Volatility yearly||20.41%||Relative Volume||241.93%||Average Volume||341.34 K|
|New High||New Low|
2020-05-08 00:31:10 | Charles River Laboratories International Inc CRL Q1 2020 Earnings Call Transcript
2020-05-07 18:52:20 | Edited Transcript of CRL earnings conference call or presentation 7-May-20 1:30pm GMT
2020-05-07 08:25:12 | Charles River Laboratories CRL Q1 Earnings and Revenues Surpass Estimates
2020-05-07 07:00:00 | Charles River Laboratories Announces First-Quarter 2020 Results
2020-04-30 12:34:04 | Charles River Laboratories CRL Reports Next Week: Wall Street Expects Earnings Growth
2020-04-29 12:08:09 | Why Horizon Kinetics is Bullish on Charles River Laboratories CRL Stock?
2020-04-20 15:24:00 | Earnings Season Preview: Medpace Near Buy Zone With Quarterly Report Due
2020-04-19 15:54:42 | Covid-19 Shines Spotlight on Clarivate
2020-03-22 22:56:25 | Is Charles River Laboratories International Inc. CRL Relatively A Good Stock To Buy?
2020-03-10 08:30:00 | Charles River Laboratories To Participate In Barclays Global Healthcare Conference
2020-03-04 08:00:00 | Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
2020-02-12 12:00:05 | Here's Why Momentum Investors Will Love Charles River Laboratories CRL
2020-02-12 10:30:00 | Charles River Labs Soars to a New High and More Strength Is Coming
2020-02-12 09:15:02 | Charles River CRL Hits Fresh High: Is There Still Room to Run?
2020-02-11 17:25:25 | Edited Transcript of CRL earnings conference call or presentation 11-Feb-20 1:30pm GMT
2020-02-11 08:25:01 | Charles River Laboratories CRL Q4 Earnings and Revenues Beat Estimates
2020-02-06 09:18:02 | Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM
2020-02-05 08:44:59 | 6 GARP Stocks to Scoop Up for Maximum Returns
2020-02-04 12:30:05 | Charles River Laboratories CRL Earnings Expected to Grow: Should You Buy?
2020-01-21 09:11:02 | 4 GARP Stocks for a Winning Portfolio
2020-01-17 15:34:17 | Still Time to Ride the Wave With Charles River
2020-01-17 09:15:02 | Icon PLC ICLR Hits Fresh High: Is There Still Room to Run?
2020-01-15 12:10:05 | Will Charles River CRL Beat Estimates Again in Its Next Earnings Report?
2020-01-13 08:00:00 | Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
2020-01-08 09:15:02 | Charles River CRL Soars to 52-Week High, Time to Cash Out?
2020-01-07 11:50:00 | Top-Rated Stocks: Charles River Labs International Sees Composite Rating Climb To 96
2020-01-03 08:30:00 | Charles River Laboratories Completes the Acquisition of HemaCare Corporation
2019-12-24 06:44:28 | Is Charles River Laboratories International, Inc.'s NYSE:CRL P/E Ratio Really That Good?
2019-12-18 19:35:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates HemaCare Corporation
2019-12-16 14:33:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HemaCare Corporation
2019-12-16 07:00:00 | Charles River Laboratories to Acquire HemaCare Corporation
2019-12-10 07:51:57 | Devon Park Drive building hits the market, could sell for a big premium